Disruptive Pharma AB (publ) (OM: GUARD)
Health Care · Biotechnology · SE
Skr1.54
+14.93% today · -94.2% 1Y
Disruptive Pharma AB (publ) (OM: GUARD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.28M and employs 12 people.
Over the last twelve months the share price has lost 94.2%, trading between 0.88 and 27.00.
GUARD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.28M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- -0.19
- 52-week high
- Skr27.00
- 52-week low
- Skr0.88
- Avg volume (3M)
- —
- Shares outstanding
- 44.59M
- Employees
- 12
- Next earnings
- —
About Disruptive Pharma AB (publ)
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
- Founded
- 2021
- Listed since
- Apr 3, 2013
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.70 | +0.28% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.24 | -1.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.